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Abstract
Introduction: Interleukin (IL)-17 is a proinflammatory cytokine that is produced largely by a unique CD4
+ T-helper
(Th) subset called Th17 cells. The development of Th17 cells is suppressed by interferon (IFN)-g produced by Th1
cells, suggesting cross-regulation between Th17 and Th1 cells. Thus, this study analyzed the balance of CD4
+ Th17
and Th1 cell responses in peripheral blood from patients with systemic lupus erythematosus (SLE) and healthy
subjects.
Methods: Twenty-five adult patients with SLE and 26 healthy subjects matched for gender and age (± 2 years)
were recruited. Peripheral blood mononuclear cells (PBMCs) from patients and healthy subjects were stimulated for
4hex vivo with phorbol myristate acetate (PMA) and ionomycin. The frequency of CD4
+ T cells producing IL-17
and/or IFN-g was measured by using flow cytometry. Expression of Th17-associated chemokine receptors CCR4 and
CCR6 on CD4
+ T cells as well as plasma levels of Th17-polarizing cytokines were assessed. Disease activity was
evaluated by the SLE disease activity index score (SLEDAI). Unpaired t test and Pearson correlation were used for
statistical analyses.
Results: Patients with SLE had an increased frequency of CD4
+IL-17
+ T cells compared with healthy subjects.
However, the frequency of CD4
+IFN-g
+ T cells was similar between the two groups, indicating an altered balance
of Th17 and Th1 cell responses in SLE. Patients with SLE also had an increased frequency of CD4
+CCR4
+CCR6
+ T
cells that are known to produce IL-17. The frequency of CD4
+IL-17
+ T cells and CD4
+CCR4
+CCR6
+ T cells correlated
with disease activity. In measuring plasma levels of the Th17-polarizing cytokines, levels of IL-6 were higher in
patients with SLE than in healthy subjects, although levels of IL-1b, IL-21, IL-23, and transforming growth factor
(TGF)-b were not different between the two groups.
Conclusions: We demonstrate an enhanced Th17 cell response that correlates with disease activity in patients with
SLE, suggesting a role for IL-17 in the pathogenesis of lupus. Our data indicate that the mechanisms involved in
balancing Th1 and Th17 regulation, as well as in producing IL-6, are aberrant in SLE, leading to an increased Th17
response. We suggest that CCR4 and CCR6 expression on CD4
+ T cells should be considered as markers of disease
activity, and that IL-17 blocking may offer a therapeutic target in SLE.
Introduction
Systemic lupus erythematosus (SLE or lupus) is an auto-
immune-mediated inflammatory disease of unknown
etiology [1,2]. The pathologic hallmarks of SLE are
altered immune responses to autoantigens with autoan-
tibody production and subsequent tissue injury mediated
by the deposition of immune complexes. In lupus, CD4
+
T cells are critical drivers of the B-cell-dependent auto-
antibody response through provision of co-stimulatory
signals and cytokines [1,3]. Infiltrates of activated T cells
are also found in tissues from affected organs such as
the kidneys and skin in lupus [4-6], although their direct
role in contribution to tissue injury is unclear.
CD4
+ T cells that orchestrate immune responses can
be divided into Th1, Th2, and Th17 cells, based on the
cytokines they primarily produce (for example, IFN-g,
IL-4, and IL-17, for Th1, Th2, and Th17 cells, respec-
tively) [7]. Differentiation of Th cells is critically
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tion provided by antigen-presenting cells (APCs) [7].
For instance, TGF-b,I L - 1 b, IL-6, IL-21, and IL-23 are
involved in developing and/or expanding Th17 cells,
whereas IFN-g and IL-4, signature cytokines required
for Th1 and Th2 differentiation, suppress Th17 cell
development [7,8].
IL-17 is a proinflammatory cytokine that is involved in
defending the host against extracellular microorganisms
such as fungi [9]. It is produced by several immune-cell
subsets including CD4
+, CD8
+, and gδ T cells [10-12], as
well as by CD3
+CD4
-CD8
- (double negative or DN) T
cells and NK cells [5,13]. IL-17 acts on a broad range of
cell types to induce cytokines (IL-6, IL-8, GM-CSF, G-
CSF), chemokines (CXCL1, CXCL10), and metallopro-
teinases [9]. It potently recruits and activates neutrophils
by induction of GM-CSF secretion [9], leading to strong
inflammatory responses. A role for IL-17 in autoimmu-
nity has been elucidated through mouse studies of
experimental autoimmune encephalomyelitis (EAE) and
collagen-induced arthritis (CIA), models for multiple
sclerosis and rheumatoid arthritis, respectively [14-16],
as well as murine lupus models [17,18]. Increased levels
of IL-17 also have been found in blood and tissues of
patients with inflammatory bowel disease and psoriasis
[19,20], suggesting a pathogenic role in human inflam-
matory diseases. Likewise, patients with SLE have ele-
vated amounts of IL-17 in serum and plasma, with an
increased frequency of T cells producing IL-17 in per-
ipheral blood [5,21-24]. Such factors may contribute to
the lupus phenotype, because IL-17 acts in conjunction
with B-cell activating factor (BAFF) in promoting the
survival and proliferation of human B cells and their dif-
ferentiation into antibody-producing cells [25].
Yet, it remains unknown why IL-17 production is
increased in lupus and whether such a finding is related
to Th1 cells producing IFN-g. Determining the balance
of Th17- and Th1-cell responses is important, because
any enhanced IL-17 activity could be secondary to
robust Th-cell responses in general that are typical of
SLE, and Th1 cytokine IFN-g is known to suppress
Th17-cell development [7,8]. Here we demonstrate that
patients with SLE have an increased frequency of circu-
lating CD4
+ T cells producing IL-17, which correlates
with disease activity, compared with healthy subjects,
whereas both groups maintain similar frequencies of
Th1 cells. In addition, plasma levels of IL-6, a cytokine
that promotes the development of Th17 cells, are higher
in patients with SLE than in healthy subjects. These
findings suggest that the balance of Th17 and Th1
responses as well as IL-6 production is dysregulated in
SLE, leading to increased IL-17 production from CD4
+
T cells, an increase that may contribute to disease
pathogenesis.
Materials and methods
Patients and healthy individuals
This work was approved by the institutional review
committee of Yale University. Twenty-five patients with
SLE were recruited from the rheumatology clinic of Yale
School of Medicine and Yale New Haven hospital. The
diagnosis of SLE was established according to the 1982
revised American College of Rheumatology criteria. Dis-
ease activity was evaluated with the SLE disease activity
index score (SLEDAI) [26]. Lupus nephritis was diag-
nosed with renal biopsy. Demographic and clinical char-
acteristics of patients with SLE are summarized in Table
1. Twenty-six healthy individuals matched for gender
and age (± 2 years) were recruited as controls. Periph-
eral blood was collected from human subjects after
obtaining informed consent.
Purification and stimulation of peripheral blood
mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from heparinized peripheral venous blood by using
Ficoll-Hypaque gradient (GE Healthcare, Piscataway,
NJ). PBMCs were washed with phosphate-buffered sal-
ine (PBS) and resuspended in RPMI 1640 media supple-
mented with 10% fetal calf serum and 1% glutamine/
penicillin/streptomycin. Cells were stimulated for 4
hours with PBS (control) or PMA (50 ng/ml; Sigma, St.
Louis, MO) and ionomycin (1 μg/ml; Sigma) in the pre-
sence of Golgiplug (BD Pharmingen, San Diego, CA) in
a tissue-culture incubator at 37°C, as previously done
[5,23,27].
Flow cytometry
PBMCs that had been stimulated with PMA/ionomycin
were stained with FITC-conjugated anti-CD3
(eBioscience, San Diego, CA) and PE-Cy5-conjugated
anti-CD4 antibodies (BD Pharmingen) followed by fixa-
tion and permeabilization by using a Cytofix/Cytoperm
kit (BD Bioscience, San Jose, CA) [27]. Cells were then
stained with PE-conjugated anti-IL-17 (eBioscience) and
Table 1 Characteristics of patients with SLE (n = 25)
Age, mean ± standard deviation (SD) years 37.7 ± 11.4
Gender, numbers of female/male patients 25/0
Medications
Number taking methotrexate 5
Number taking azathioprine 5
Number taking mycophenolate mofetil 5
Number taking cyclophosphamide 1
Number taking systemic corticosteroids 14
Prednisone dose, mean ± SD, mg/day 15.89 ± 8.96
Number of patients with nephritis 12
SLE, systemic lupus erythematosus.
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gen). Fresh PBMCs were stained with biotin-conjugated
anti-CCR6 and PE-conjugated anti-CCR4 antibodies (all
from BD Pharmingen) followed by staining with strepta-
vidin-Alexa Fluor 488 [28]. Stained cells were analyzed
on a FACSCalibur flow cytometer (BD Biosciences).
Collected data were analyzed by using FlowJo software
(Tree Star, Ashland, OR).
ELISA and multiplex cytokine assay
Plasma was separated from heparinized peripheral blood
and stored in -80°C for later cytokine assays. Plasma
cytokines were analyzed by using commercially available
ELISA kits (TGF-b and IL-23 from R&D Systems, Min-
neapolis, MN; IL-21 from eBioscience) or Bio-Plex Pro
h u m a nc y t o k i n ea s s a yk i t( I L - 1 b, IL-6, IL-10; Bio-Rad,
Hercules, CA) in duplicate, according to the manufac-
turers’ instructions. The low limits of detection (pg/ml)
for IL-1b, IL-6, IL-10, TGF-b, IL-21, and IL-23 were 0.8,
1.1, 0.9, 31, 31, and 6.8, respectively.
Statistical analysis
Quantitative data were expressed as the mean ± SD.
Unpaired t test and Pearson correlation were used for
statistical analyses. A value of P < 0.05 was considered
statistically significant. All statistical analyses were per-
formed by using SPSS statistical software version 16
(SPSS Inc., Chicago, IL).
Results
Patients with SLE have an increased frequency of Th17
cells but not Th1 cells in peripheral blood, with an
impaired balance of Th17 and Th1 responses
We investigated whether the frequency of Th17 and
Th1 cells in patients with SLE differed from that in
healthy individuals. After stimulating PBMCs for 4
hours with PMA and ionomycin, we identified CD4
+ T
cells producing IL-17, IFN-g, or both, by using flow
cytometry (Figure 1a; representative example) [27].
Patients with SLE had an increased frequency of Th17
cells compared with healthy controls (mean ± SD, 1.8 ±
1.26% versus 0.6 ± 0.27%; P < 0.001) (Figure 1b), as well
as an increased frequency of IL-17 and IFN-g double-
positive cells (0.46 ± 0.41% versus 0.21 ± 0.14%; P =
0.005) (Figure 1c), although patients and controls had
similar frequencies of Th1 cells(17.1 ± 9.23% versus 15.5
± 5.47%; P = 0.457) (Figure 1d). Of interest, a recent
study reported expansion of IL-17-secreting DN T cells
in the peripheral blood of lupus patients after long-term
(>5 days) in vitro stimulation [5]. We also noticed an
increased frequency of IL-17-producing cells in CD3
+CD4
- T cells that included DN T cells in patients with
SLE compared with healthy controls (1.65 ± 1.45% ver-
sus 0.87 ± 0.53%; P = 0.016). We next assessed the
relation of Th17 to Th1 cells in patients and controls.
In the latter, the frequency of IL-17
+ cells directly corre-
lated with the frequency of IFN-g
+ cells (r =0 . 4 7 3 ;P =
0.015), although a similar correlation was not observed
in patients with SLE (Figure 2a). We next determined
the ratio of CD4
+ T cells producing IL-17 to the same
cells producing IFN-g because patients with SLE could
have an increased frequency of both cell subsets without
an alteration in the Th17/Th1 ratio. The ratio of Th17
to Th1 cells was higher in patients with SLE than in
healthy controls (Figure 2b). Taken together, these
observations indicate that patients with SLE have an
aberrant CD4
+ T-cell response, resulting in a propensity
toward an increased frequency of Th17 cells.
The frequency of Th17 cells correlates with disease
activity in patients with SLE
We determined the relation between the frequency of
CD4
+IL-17
+ T cells and disease activity as measured by
SLEDAI in patients with SLE. A strong correlation
between the two parameters was observed (r = 0.597; P =
0.003) (Figure 3a). Although the frequency of IL-17 and
IFN-g double-positive cells tended toward a correlation
with SLEDAI scores, it was not statistically significant (r =
0.304; P = 0.138) (Figure 3b). By contrast, no clear correla-
tion was found between the frequency of Th1 cells and
disease activity (r = -0.086; P = 0.682) (Figure 3c). We also
determined the correlation of SLEDAI scores with the fre-
quency of CD3
+CD4
-IL-17
+ T cells which included DN T
cells as well as with the frequency of total CD3
+IL-17
+ T
cells that contained both CD4
+ and DN T-cell subsets.
Although a trend was noted toward the positive correla-
tion between the frequency of CD3
+CD4
-IL-17
+ T cells
and SLEDAI scores, it was not statistically significant (r =
0.344; P = 0.092). The frequency of CD3
+ Tc e l l sp r o d u -
cing IL-17 (total IL-17
+ T cells) correlated with SLEDAI
scores (r = 532; P = 0.006). We prospectively analyzed the
frequency of CD4
+IL-17
+ T cells in two patients with SLE
who had high disease activity at the enrollment. With
improved disease activity, the frequency of this cell subset
substantially decreased, whereas the frequency of CD4
+IFN-g
+ T cells increased (Figure 3d).
We next assessed the relation of the Th17-cell
response with lupus nephritis and medications. The fre-
quency of these cells tended to be higher in lupus
patients with nephritis than in those without nephritis,
although the difference was not statistically significant
(Figure 3e). No difference was observed in the frequency
of CD4
+IL-17
+ T cells between lupus patients who took
or did not take glucocorticoids. The frequency of this
cell subset also was similar in lupus patients taking and
not taking immunosuppressive drugs, including
azathioprine, methotrexate, mycophenolate mofetil, and
cyclophosphamide (data not shown).
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+CCR4
+CCR6
+ T cells in peripheral blood
Previous studies reported that CD4
+ T cells producing IL-
17 express CCR4 and CCR6 [28]. Thus, we measured the
frequency of these cells in the peripheral blood of patients
with SLE and in healthy controls (Figure 4a). An increased
frequency of CD4
+CCR4
+CCR6
+ T cells was found in the
former group (7.32 ± 7.27% versus 2.18 ± 2.16%; P =
0.021) (Figure 4a and 4b), with a correlation with the fre-
quency of Th17 cells (r = 0.748; P =0 . 0 0 8 )( F i g u r e4 c ) .
Furthermore, a correlation was found between the fre-
quency of CD4
+CCR4
+CCR6
+ T cells and disease activity
(r = 0.645; P = 0.013) (Figure 4d). In a manner analogous
to that of Th17 cells, the frequency of CD4
+CCR4
+CCR6
+
T cells decreased as disease activity improved (Figure 4e).
Th17-polarizing cytokines in plasma of patients with SLE
and healthy controls
The development of Th17 cells is critically dependent on
the cytokine milieu, with IL-1b,T G F - b, IL-6, IL-21, and IL-
23 promoting Th17-cell differentiation and expansion
[29-34]. Thus, we measured these cytokines in plasma to
investigate whether altered production of such cytokine(s)
could potentially account for the increased Th17-cell
response in SLE. We found increased levels of IL-6 in
plasma of lupus patients compared with those in healthy
controls (16.03 ± 20.03 pg/ml versus 6.29 ± 4.09 pg/ml; P =
0.040) (Figure 5b). Plasma IL-21 levels also tended to be
higher in patients than in controls, although the difference
was not statistically significant (615.96 ± 425.15 pg/ml ver-
sus 450.92 ± 96.67 pg/ml; P = 0.099) (Figure 5c); however,
plasma levels of other Th17-polarizing cytokines, including
IL-1b, IL-23, and TGF-b, were similar between the two
groups. As previously reported [35,36], plasma levels of IL-
10 were higher in patients with SLE than in healthy controls
(3.40 ± 4.79 pg/ml versus 1.11 ± 0.38 pg/ml; P = 0.041)
(Figure 5f).
Discussion
We present data demonstrating an enhanced Th17-cell
response in patients with SLE compared with healthy
controls. More important, the increased frequency of
Figure 1 Patients with SLE have an increased frequency of Th17 cells but not Th1 cells. PBMCs from patients with SLE (n = 25) and
healthy control subjects (HC, n = 26) were stimulated for 4 hours ex vivo with PMA and ionomycin or PBS (control) in the presence of
Golgiplug. The frequency of CD4
+ T cells producing IL-17 and/or IFN-g was measured by using flow cytometry. (a) Representative dot plots
showing CD4
+ T cells producing IL-17 and/or IFN-g. (b) The frequency (% of CD4
+IL-17
+ T cells, CD4
+IL-17
+IFN-g
+ T cells and CD4
+IFN-g
+ T cells
in patients with SLE and in healthy control subject (HC). Numbers in dot plots indicate the frequency of cells for each quadrant. Bars show the
means.
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potential role for this cytokine in disease pathogenesis.
Although the mechanism(s) for these findings remains
to be determined, our results indicate that the Th1 and
Th17 cell balance, as well as in IL-6 production, are dys-
regulated in SLE, leading to the increased frequency of
CD4
+IL-17
+ T cells in patients.
Although CD4
+ T cells are pathogenic in murine, and
apparently in human, lupus [2], the contribution of indi-
vidual Th-cell subsets to disease remains unclear, parti-
cularly in humans. Th1 cells appear to promote renal
inflammation [37]. Recent studies have reported
increased levels of serum or plasma IL-17 as well as an
increased frequency of peripheral blood cells producing
IL-17 in patients with SLE compared with healthy con-
trols [5,21-24]. IL-17 can be produced from different
types of immune cells including CD4
+ Tc e l l s ,C D 8
+ T
cells, and gδ-T cells, as well as DN T cells and NK cells
[5,10,11,13]. Of interest, Crispin et al. [5] showed expan-
sion of IL-17-secreting DN T cells in the peripheral
blood of lupus patients after long-term (>5 days) in
vitro stimulation. We, conversely, studied CD4
+ (not
DN) T cells directly ex vivo, a much better reflection of
the in vivo situation than long-term culture, a situation
that can artificially expand a potentially trivial popula-
tion, or conversely, lead to contraction of an expanded
Figure 2 Correlation of Th17 and Th1 response is dysregulated in patients with SLE. (a) The frequency (% of CD4
+IL-17
+ T cells correlates
with the frequency of CD4
+IFN-g
+ T cells in healthy control subjects (HC, n = 26) but not in patients with SLE (n = 25). (b) Patients with SLE
have a higher Th17/Th1 ratio (frequency of CD4
+IL-17
+ T cells/frequency of CD4
+IL-IFN-g
+ T cells) compared with healthy control subjects. Bars
and numbers in (b) indicate the means.
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IL-17-producing cells in CD3
+CD4
- T cells that included
DN T cells in patients with SLE compared with healthy
controls. Yang et al. [23] revealed an increased fre-
quency of CD3
+CD8
-IL-17
+ T cells in the blood of
lupus patients compared with healthy controls. The
expanded population of CD3
+CD8
-IL-17
+ T cells identi-
fied by this study must have included DN T cells. Of
interest, in the same study, lupus patients had increased
IFN-g gene expression in PBMCs and higher serum
levels of the same cytokine compared with healthy con-
trols, as measured by quantitative PCR and ELISA,
respectively. IFN-g has multiple cellular sources includ-
ing CD4
+,C D 8
+ T cells and innate immune cells,
including macrophages and NK cells. Thus, these assays
could not tell whether such findings were secondary to
increased IFN-g production from CD4
+ T cells. This is a
critical point, because any increased frequency of IL-17-
producing T cells could be secondary to enhanced Th
function in general. Furthermore, numbers of Th17 cells
should be investigated with an analysis of Th1 cells,
given that IFN-g can suppress the development of IL-
17-producing cells [8]. Indeed, our study demonstrated
a dysregulated balance between Th1 and Th17 cells in
SLE, a novel finding. Because very few CD8
+ T cells
produced IL-17 in PBMCs from patients with SLE and
healthy controls after 4 hours of PMA and ionomycin
stimulation (data not shown), our work indicates that
increased IL-17 production in patients with SLE is con-
tributed predominantly by CD4
+ T cells and DN T cells.
We found a strong positive correlation between the
frequency of Th17 cells and disease activity. Although
this finding suggests that the increased IL-17 production
in lupus is biologically relevant, the precise role for this
cytokine in the pathogenesis of lupus has yet to be elu-
cidated. A recent study reported that IL-17 alone or in
combination with BAFF promoted the survival and pro-
liferation of human B cells and their differentiation into
antibody-producing cells [25]. This observation provides
a novel insight into understanding the pathogenic role
for IL-17 in lupus because aberrant B-cell immunity
with autoantibody production is essential for tissue
damage and inflammation in human and murine lupus.
Of interest, we found increased levels of plasma IL-10,
Figure 3 The frequency of IL-17
+ CD4
+ T cells correlates with disease activity. (a-c) Relation between SLEDAI score and the frequency (%)
of (a) CD4
+IL-17
+ T cells, (b) CD4
+IL-17
+IFN-g
+ T cells and (d) CD4
+IFN-g
+ T cells in patients with SLE (n = 25). (d) Dot plots showing the
frequency of CD4
+ T cells producing IL-17 and/or IFN-g in a patients with SLE at the times of high and low disease activities (SLEDAI score, 16
and 6, respectively). Representative data from two patients with SLE. (e) The frequency of CD4
+IL-17
+ T cells in patients with (+, n = 11) and
without (-, n = 14) lupus nephritis. Numbers in dot plots indicate the frequency of cells for each quadrant. Bars show the means.
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be linked to increased B-cell production of IL-10 in
lupus that also potently promotes humoral immunity
[2]. In our study, lupus patients with nephritis had a
trend toward an increased frequency of CD4
+IL-17
+ T
cells and CD3
+CD4
-IL-17
+ T cells compared with those
without nephritis. Infiltrates of IL-17 producing T cells,
including CD4
+ and DN T cells, have been found in
lupus nephritis. In addition, IL17 gene expression was
detected in T cells infiltrating the kidneys and in urine
sediments of lupus patients [38,39]. These findings sup-
p o r tt h ep o s s i b l ep a t h o l o g i cs i g n i f i c a n c eo fo u rf i n d i n g s
[5].
The mechanism for increased IL-17 production in
patients with SLE is unclear. Although this finding
could be secondary to increased CD4
+ T-cell responses
in general, the results of our study showed that the
frequency of Th17 but not Th1 cells was increased in
patients with SLE compared with healthy controls.
Furthermore, the positive correlation between the fre-
quencies of Th17 and Th1 cells that was found in
healthy controls was disrupted in lupus patients. These
observations indicate that the balance of Th17 and Th1
cell responses is dysregulated in SLE, leading to
enhanced Th17 cell response. Thus, we explored a
potential role for polarizing cytokines in promoting IL-
17 production in SLE, because the development of Th
s u b s e t si sc r i t i c a l l yd e p e n dent on the cytokine milieu.
Plasma levels of IL-6 were higher in patients with SLE
than in healthy subjects, suggesting the possible involve-
ment of this cytokine in enhancing the Th17-cell
response we observed. In line with this finding,
increased circulating levels of IL-6 are found in patients
with SLE [35]. We also noticed that patients with SLE
Figure 4 Patients with SLE have an increased frequency of CD4
+CCR4
+ CCR6
+ Tc e l l s . The frequency of CCR4
+ CCR6
+ CD4
+ T cells in
peripheral blood was analyzed in patients with SLE and healthy control subjects by using flow cytometry. (a) Representative dot plots showing
CD4
+ T cells expressing CCR4 and CCR6. (b) The frequency (%) of CD4
+CCR4
+CCR6
+ T cells in patients with SLE (n = 14) and healthy control
subject (HC, n = 25). (c) Correlation between the frequencies of CD4
+IL-17
+ T cells and CD4
+CCR4
+CCR6
+ T cells in patients with SLE (n = 11).
(d) Correlation between the frequency of CD4
+CCR4
+CCR6
+ T cells and SLEDAI score in patients with SLE (n = 14). (e) Representative dot plots
showing the frequency of CD4
+ T cells expressing CCR4 and/or CCR6 in a patients with SLE at the times of high and low disease activities
(SLEDAI score, 16 and 6, respectively). Representative data from three patients with SLE. Numbers in dot plots indicate the frequency of cells for
each quadrant. Bars show the means.
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kine that can be produced from Th17 cells and pro-
motes both humoral and Th17 immune responses
[29,40]. In contrast to IL-6, plasma levels of IL-1b,I L -
23, and TGF-b were similar between the two groups.
We believe that further studies are warranted to deter-
mine the mechanism for increased IL-17 production
from CD4
+ T cells in human lupus.
Several cell-surface molecules were reported as poten-
tial markers for Th17 cells. To date, the best-known
molecules are CCR4 and CCR6 [28]. We noticed a
strong correlation between the frequencies of CD4
+IL-
17
+ Tc e l l sa n dC D 4
+CCR4
+CCR6
+ T cells in the per-
ipheral blood of lupus patients. The frequencies of both
cell subsets correlated with disease activity, as measured
cross sectionally and prospectively, raising the possibility
of using such cell measurements in assessing disease
activity in patients with SLE. Clinical studies with large
numbers of patients will help address this point. In con-
t r a s tt oo u ro b s e r v a t i o n ,ar e c e n ts t u d yd i dn o tf i n da n
increased frequency of CCR4
+CCR6
+ T cells in
peripheral blood of lupus patients [5]. Although the rea-
son for this discrepancy is not clear, it could be related
to the fact that this study noticed an increased fre-
quency of DN T cells but not CD4
+ T cells producing
IL-17. Of interest, CD4
+CCR4
+CCR6
- Tc e l l sa l s o
appeared to expand in active lupus patients (Figure 4a
and 4e). However, CD4
+CCR4
+CCR6
+ T cells and CD4
+CCR4
+CCR6
- T cells have different capacities for cyto-
kine production. The former subset, but not the latter,
can produce large amounts of IL-17 [28].
Conclusions
In summary, our study provides evidence of a role for
IL-17 in the pathogenesis of SLE, with the demonstra-
tion of an increased frequency of Th17 cells in the per-
ipheral blood of lupus patients, and a correlation of the
frequency of these cells with disease activity. Although
the mechanism underlying our findings is yet to be
determined, it appears that factor(s) involved in balan-
cing Th17 and Th1 cell responses as well in producing
IL-6 are dysregulated in SLE. Our data offer a scientific
Figure 5 Plasma levels of Th17-driving cytokines and IL-10 in patients with SLE and healthy controls. Plasma levels of Th17-polarizing
cytokinesg(IL-1b, IL-6, IL-21, TGF-b, and IL-23) and IL-10 were measured in patients with SLE and healthy control subjects (HCs) by using ELISA or
multiplex cytokine assay. Bars show the means. Samples from 21 patients with SLE and 24 healthy controls for cytokines except TGF-b (n =2 0
and n = 19 for lupus patients and healthy controls, respectively).
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as Th17-associated molecules CCR4 and CCR6 as biolo-
gic markers for disease activity in human lupus. Our
observations also raise the possibility of anti-IL-17 ther-
apy in controlling disease activity in SLE.
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